Filtered By:
Source: Clinical Drug Investigation
Cancer: Non-Small Cell Lung Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Dabrafenib Plus Trametinib for BRAF V600E-Mutant Non-small Cell Lung Cancer: A Patient Case Report
We report the case of a 70-year-old Asian woman (never smoker) who was diagnosed with lung adenocarcinoma in May 2014. Testing at diagnosis was negative for programmed death ligand 1 orEGFR,ALK, andROS1 alterations. She was started on carboplatin-pemetrexed-bevacizumab and maintenance bevacizumab but progressed in September 2015. Subsequently, she progressed on second-line nivolumab and third-line docetaxel. In March 2016, pleural fluid obtained at diagnosis tested positive for theBRAF V600E mutation and she received dabrafenib plus trametinib. She experienced rapid tumor shrinkage and symptom improvement and became able t...
Source: Clinical Drug Investigation - June 26, 2019 Category: Drugs & Pharmacology Source Type: research
